Cargando…

An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro

BACKGROUND: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and their nanometer-scale sizes may allow for passive accumulation in solid tumors....

Descripción completa

Detalles Bibliográficos
Autores principales: Fix, Samantha M., Novell, Anthony, Yun, Yeoheung, Dayton, Paul A., Arena, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260003/
https://www.ncbi.nlm.nih.gov/pubmed/28127427
http://dx.doi.org/10.1186/s40349-017-0085-z
_version_ 1782499321737904128
author Fix, Samantha M.
Novell, Anthony
Yun, Yeoheung
Dayton, Paul A.
Arena, Christopher B.
author_facet Fix, Samantha M.
Novell, Anthony
Yun, Yeoheung
Dayton, Paul A.
Arena, Christopher B.
author_sort Fix, Samantha M.
collection PubMed
description BACKGROUND: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and their nanometer-scale sizes may allow for passive accumulation in solid tumors. As a first step towards the goal of extravascular cell permeabilization, we aim to characterize the sonoporation potential of a low-boiling point formulation of PCCAs in vitro. METHODS: Parameters to induce acoustic droplet vaporization and subsequent microbubble cavitation were optimized in vitro using high-speed optical microscopy. Sonoporation of pancreatic cancer cells in suspension was then characterized at a range of pressures (125–600 kPa) and pulse lengths (5–50 cycles) using propidium iodide as an indicator molecule. RESULTS: We achieved sonoporation efficiencies ranging from 8 ± 1% to 36 ± 4% (percent of viable cells), as evidenced by flow cytometry. Increasing sonoporation efficiency trended with increasing pulse length and peak negative pressure. CONCLUSIONS: We conclude that PCCAs can be used to induce the sonoporation of cells in vitro, and our results warrant further investigation into the use of PCCAs as extravascular sonoporation agents in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40349-017-0085-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5260003
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52600032017-01-26 An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro Fix, Samantha M. Novell, Anthony Yun, Yeoheung Dayton, Paul A. Arena, Christopher B. J Ther Ultrasound Research BACKGROUND: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and their nanometer-scale sizes may allow for passive accumulation in solid tumors. As a first step towards the goal of extravascular cell permeabilization, we aim to characterize the sonoporation potential of a low-boiling point formulation of PCCAs in vitro. METHODS: Parameters to induce acoustic droplet vaporization and subsequent microbubble cavitation were optimized in vitro using high-speed optical microscopy. Sonoporation of pancreatic cancer cells in suspension was then characterized at a range of pressures (125–600 kPa) and pulse lengths (5–50 cycles) using propidium iodide as an indicator molecule. RESULTS: We achieved sonoporation efficiencies ranging from 8 ± 1% to 36 ± 4% (percent of viable cells), as evidenced by flow cytometry. Increasing sonoporation efficiency trended with increasing pulse length and peak negative pressure. CONCLUSIONS: We conclude that PCCAs can be used to induce the sonoporation of cells in vitro, and our results warrant further investigation into the use of PCCAs as extravascular sonoporation agents in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40349-017-0085-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-24 /pmc/articles/PMC5260003/ /pubmed/28127427 http://dx.doi.org/10.1186/s40349-017-0085-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fix, Samantha M.
Novell, Anthony
Yun, Yeoheung
Dayton, Paul A.
Arena, Christopher B.
An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
title An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
title_full An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
title_fullStr An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
title_full_unstemmed An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
title_short An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
title_sort evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260003/
https://www.ncbi.nlm.nih.gov/pubmed/28127427
http://dx.doi.org/10.1186/s40349-017-0085-z
work_keys_str_mv AT fixsamantham anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT novellanthony anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT yunyeoheung anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT daytonpaula anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT arenachristopherb anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT fixsamantham evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT novellanthony evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT yunyeoheung evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT daytonpaula evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro
AT arenachristopherb evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro